eli lilly clinical trials retatrutide Phase 3 obesity trial results 2026 FOX6 - Retatrutide, Eli Lilly's

By May 2025, prescribing reached 1.2% of all prescriptions, nearly double AOM semaglutides prescribing rates

NRG, RG, LK, AP, CS, SA, AB, MVC, AC, CG, MH, JM, CM, MS, AIT, HYY, IWA and QZ designed and performed the experiments and analysed the data in collaboration with or under the guidance of GL, RR and PR

The obesity trial studied a substantially heavier population, while lean-recomposition reports describe a lighter one

FDA submission has not yet been made

10.1007/s10549-017-4523-y 29 StoccoC

This review study analyzes human and animal trials of various GLP-1 medications for their role in addressing the hallmarks of aging, such as mitochondrial function and oxidative stress, including low-dose protocols via injection for Parkinson's patients on exenatide